Mechanism and Clinical Research Progress of Puerarin in Treatment of Chronic Heart Failure
10.13422/j.cnki.syfjx.20251245
- VernacularTitle:葛根素治疗慢性心力衰竭的机制与临床研究进展
- Author:
Wenjie LU
1
;
Siqi ZHONG
1
;
Lu ZHANG
1
;
Wenting LIN
1
;
Zhijun ZENG
1
;
Shaohua WANG
2
Author Information
1. Research Center for Differentiation and Development of Traditional Chinese Medicine（TCM） Basic Theory， Jiangxi University of TCM， Nanchang 330004，China
2. School of Sports Health， Jiangxi University of TCM， Nanchang 330004，China
- Publication Type:Journal Article
- Keywords:
chronic heart failure;
puerarin;
traditional Chinese medicine therapy;
multi-target mechanism;
clinical translation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(8):327-336
- CountryChina
- Language:Chinese
-
Abstract:
Chronic heart failure （CHF） is an end-stage cardiac syndrome driven by multiple factors. Its pathological process involves interactions of multiple pathways such as energy metabolism dysfunction， neuroendocrine dysregulation， and myocardial fibrosis. Although current clinical medicine can alleviate symptoms through single-target approaches， significant limitations in reversing cardiac remodeling and disease progression remain. Puerarin， a major bioactive isoflavone constituent derived from Pueraria lobata， exhibits multidimensional pharmacological effects， such as vasodilatory effects， regulation of neuroendocrine balance， enhancement of metabolic homeostasis， and suppression of myocardial apoptosis. This review systematically integrated puerarin's multi-target regulatory network， elucidating its mechanisms such as improving energy metabolism by AMP-activated protein kinase/mechanistic target of rapamycin （AMPK/mTOR） pathway， inhibiting fibrosis mediated by transforming growth factor-β （TGF-β）/Smad signals， and attenuating oxidative-inflammatory cascades by regulating nuclear factor erythroid 2 （E2）-related factor 2/nuclear transcription factor-κB（Nrf2/NF-κB） axis. Clinical research data was used to validate its efficacy in improving the left ventricular ejection function and reducing the therapeutic potential of cardiovascular events' risks. The study proposed that puerarin's "systemic regulation" characteristic breaks through the limitations of traditional single-target drugs and prospected its clinical translation pathway based on metabolomics and nano-delivery technology， offering an integrative perspective from molecular mechanisms to precise therapy for the research on modernization of traditional Chinese medicine.
